Clinuvel Pharmaceuticals Ltd.
CUVL
NASDAQ6.90
USD
+0.03
- -
CIK
0001290877
ISIN
US1887691038
CUSIP
188769103
Return %
Stock
S&P500
1Y
-2.13
19.43
3Y
-2.13
76.01
5Y
-2.13
74.94
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Philippe Jacques Wolgen
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 535 Bourke Street Melbourne VIC Australia 3000
- IPO Date
- Jul 13, 2026
- CIK
- 0001290877
- Website
- clinuvel.com
- Similar Companies
- Business
- Clinuvel Pharmaceuticals Ltd. conducts research, development, and commercialisation of innovative therapeutics for serious diseases with a focus on photomedicine and complement biology, aiming to improve patient outcomes through targeted treatment options and rare disease management. Main Products and Services - Hit products and primary therapies: Scenesse (afamelotide) is the company’s flagship injectable analogue designed to prevent phototoxic reactions in erythropoietic protoporphyria (EPP) and early-stage photoprotection in other conditions; represents the core therapy and principal revenue driver. - Pipeline and development products: Product candidates and preclinical/clinical-stage therapies targeting genetic and metabolic disorders with phototherapeutic or pigmentary components; include next-generation versions or adjunctive formulations of Scenesse and novel photomedicine programs. - Research and development services: End-to-end R&D capabilities including pharmacology, toxicology, and translational science; internal laboratory operations support for preclinical studies, process development, and early-stage clinical planning. - Regulatory and quality services: Regulatory strategy, data management, pharmacovigilance, and quality assurance activities aligned with global standards to support approvals, manufacturing licensure, and post-market surveillance. - Manufacturing and supply: Finished pharmaceutical product manufacture, formulation development, fill-finish operations, packaging design, and global distribution coordination for commercial products and clinical trial materials. - Commercialisation and medical affairs: Market access activities, pricing and reimbursement strategies, medical education programs, and engagement with healthcare professionals to support product adoption and clinical guidelines. Latest Major Company Changes - Strategic partnerships and alliances: Entered collaborations with biopharmaceutical and contract manufacturing entities to advance pipeline programs, enhance manufacturing capacity, and expand global reach; agreements include co-development or licensing arrangements to accelerate clinical programs and geographic expansion. - Financing and corporate activity: Completed funding rounds and capital raise activities to support R&D and late-stage development; ongoing considerations of strategic equity investments or debt facilities to bolster liquidity for clinical and regulatory milestones. - Product launches and pipeline updates: Initiates or expands clinical development for follow-on photomedicine products or combination therapies; announces new trial initiations, expansion of existing studies, or expansion into additional indications linked to pigmentary disorders or rare diseases. - Strategic shifts and expansions: Reallocates resources toward high-potential photomedicine assets, broadening global regulatory submissions, and pursuing expansion in geographies with favorable reimbursement environments; may include organizational realignments to streamline development pipelines. - Corporate restructurings or name changes: Any recent reorganizations internal to corporate structure or branding adjustments to reflect expanded focus on photomedicine platforms and added indications, with disclosures on governing bodies and subsidiaries. - Operational changes: Enhancements to manufacturing scale, supply chain resilience, and quality systems; increases in clinical trial sites and investigator networks; optimization of clinical trial logistics and data management capabilities within the last 1-2 years. Additional Context - Industry and segments: Biopharmaceuticals with a specialization in photomedicine and pigmentary disorder treatments; operates across clinical development, regulatory affairs, and commercialisation in rare diseases and conditions requiring controlled light exposure or color biology therapeutics. - Target markets and customers: Healthcare systems, specialist clinicians (dermatology, hematology, rare disease centers), patient advocacy groups, and regulators; direct relationships with hospitals, clinics, and contract manufacturers. - Geographic operations: Global footprint including research facilities and commercial activities across multiple regions; distribution networks and regulatory access in North America, Europe, and select Asia-Pacific markets. - Founding year and headquarters: Founded in 1999; headquartered in Melbourne, Australia, with translational and development activities aligned to regional and international regulatory environments. - Subsidiaries and parent relationships: Operates through a corporate structure with parent company governance and subsidiary entities to manage regional marketing, clinical operations, and manufacturing partner networks; affiliated entities coordinate research collaborations and distribution agreements within the photomedicine portfolio.